Specialty Drug Approval
New Biologic Drug Approved for Psoriasis: Ilumya® (tildrakizumab-asmn)
In March 2018, the U.S. Food and Drug Administration (FDA) approved Ilumya® (tildrakizumab-asmn) for the treatment of adults with moderate to severe plaque psoriasis. It is indicated specifically for patients who are candidates for systemic therapy or phototherapy and is given as a subcutaneous injection. Ilumya acts by binding to interleukin-23 (IL-23), thereby preventing the interleukin from interacting with its receptor. Inhibition of this interaction prevents the release of inflammatory mediators. Tildrakizumab is expected to compete with the other IL-23 antagonists indicated for plaque psoriasis: Tremfya® (guselkumab) and Stelara® (ustekinumab).